These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22112348)

  • 1. Novel agents targeting nitric oxide.
    Kampoli AM; Tousoulis D; Tentolouris C; Stefanadis C
    Curr Vasc Pharmacol; 2012 Jan; 10(1):61-76. PubMed ID: 22112348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies targeting vascular endothelium.
    Tousoulis D; Antoniades C; Koumallos N; Marinou K; Stefanadi E; Latsios G; Stefanadis C
    Endothelium; 2006; 13(6):411-21. PubMed ID: 17169773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic strategies targeting endothelial function in humans: clinical implications.
    Lee R; Channon KM; Antoniades C
    Curr Vasc Pharmacol; 2012 Jan; 10(1):77-93. PubMed ID: 22112349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial dysfunction in conduit arteries and in microcirculation. Novel therapeutic approaches.
    Tousoulis D; Simopoulou C; Papageorgiou N; Oikonomou E; Hatzis G; Siasos G; Tsiamis E; Stefanadis C
    Pharmacol Ther; 2014 Dec; 144(3):253-67. PubMed ID: 24928320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis.
    Herman AG; Moncada S
    Eur Heart J; 2005 Oct; 26(19):1945-55. PubMed ID: 15911567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of nitric oxide on endothelial function.
    Tousoulis D; Kampoli AM; Tentolouris C; Papageorgiou N; Stefanadis C
    Curr Vasc Pharmacol; 2012 Jan; 10(1):4-18. PubMed ID: 22112350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitric oxide-mediated endothelial dysfunction--is there need to treat?
    Tiefenbacher CP; Kreuzer J
    Curr Vasc Pharmacol; 2003 Jun; 1(2):123-33. PubMed ID: 15320839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial dysfunction: potential clinical implications.
    Tousoulis D; Koutsogiannis M; Papageorgiou N; Siasos G; Antoniades C; Tsiamis E; Stefanadis C
    Minerva Med; 2010 Aug; 101(4):271-84. PubMed ID: 21030938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of endothelial function: targets for nutritional and pharmacological interventions.
    Sudano I; Spieker LE; Hermann F; Flammer A; Corti R; Noll G; Lüscher TF
    J Cardiovasc Pharmacol; 2006; 47 Suppl 2():S136-50; discussion S172-6. PubMed ID: 16794451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities.
    Kietadisorn R; Juni RP; Moens AL
    Am J Physiol Endocrinol Metab; 2012 Mar; 302(5):E481-95. PubMed ID: 22167522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endothelium and nitric oxide].
    Garaliene V
    Medicina (Kaunas); 2008; 44(7):564-9. PubMed ID: 18695354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial dysfunction--can we improve it?
    Wojtczak A
    Acta Pol Pharm; 2004 Dec; 61 Suppl():32-4. PubMed ID: 15909932
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide.
    Landmesser U; Drexler H
    J Hypertens Suppl; 2006 Mar; 24(1):S39-43. PubMed ID: 16601572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Arginine and statins: relationship between the nitric oxide pathway and the atherosclerosis development].
    Rasmusen C; Cynober L; Couderc R
    Ann Biol Clin (Paris); 2005; 63(5):443-55. PubMed ID: 16230278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities.
    Thomas SR; Witting PK; Drummond GR
    Antioxid Redox Signal; 2008 Oct; 10(10):1713-65. PubMed ID: 18707220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease.
    Lyons D
    Int J Cardiol; 1997 Dec; 62 Suppl 2():S101-9. PubMed ID: 9488201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
    Enseleit F; Hürlimann D; Lüscher TF
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Endothelial dysfunction. Therapeutic and prognostic issues].
    Kelm M; Strauer BE
    Internist (Berl); 1999 Dec; 40(12):1300-7. PubMed ID: 10642917
    [No Abstract]   [Full Text] [Related]  

  • 19. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin.
    Kalinowski L; Dobrucki LW; Brovkovych V; Malinski T
    Circulation; 2002 Feb; 105(8):933-8. PubMed ID: 11864921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
    Jantzen F; Könemann S; Wolff B; Barth S; Staudt A; Kroemer HK; Dahm JB; Felix SB; Landsberger M
    J Physiol Pharmacol; 2007 Sep; 58(3):503-14. PubMed ID: 17928646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.